Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options

The piece evaluates selling a January 2027 $15 put on Sarepta Therapeutics (SRPT), noting the contract yields a $3.20 premium equating to a 22.2% annualized return but only results in share ownership if SRPT falls ~26.4% from $20.40 to the strike. If exercised the effective cost basis would be $11.80 per share before commissions; the article flags the stock's high trailing-12-month volatility of 119% (251 trading days) as a key risk input for judging whether the premium compensates for downside exposure.

Analysis

Market structure: Elevated SRPT implied/trailing volatility (119%) creates clear winners — option premium sellers (income funds, market makers) and exchanges (NDAQ) that earn fees on higher options volumes — and losers — passive single‑name equity holders if a binary clinical/FDA event occurs. The quoted Jan‑2027 $15 put yields ~22.2% annualized versus spot $20.40, pricing in ~26% downside to the strike and ~42% to the premium‑adjusted basis ($11.80) if assigned; that asymmetry favors disciplined cash‑secured put sellers but concentrates tail risk.

Risk assessment: Tail risks are asymmetric and binary — adverse trial/FDA outcomes, manufacturing or litigation could drive >50% moves within days; short term (days–weeks) IV will reprice around data; medium (3–12 months) cash burn and partnering/licensing updates matter; long term (1–3 years) commercial execution and reimbursement determine value. Hidden dependencies include orphan‑drug pricing dynamics and milestone payments; catalysts to watch: next 12 months of clinical readouts, FDA advisory dates and quarterly cash burn statements.

Trade implications: Direct play — consider selling cash‑secured Jan‑2027 SRPT $15 puts size 1–2% portfolio to collect ~ $3.20 premium (target annualized ~22%), with hard stop/roll if SRPT < $12 or position loss >30%. Defensive alternative — buy Jan‑2027 $10/$15 put spread (0.5–1% portfolio) to hedge binary downside at capped cost. Tactical pair — rotate 2–3% into NDAQ (long) to capture structural option flow upside if IV stays elevated; reduce single‑name biotech exposure by 3–5% into diversified biotech/healthcare ETFs over 3 months.

Contrarian angles: The market may underappreciate that selling premium is profitable if you accept assignment at a ~$11.80 basis; however history of binary biotech blowups (60–80% moves) means premium income can vanish quickly. If many participants crowd into cash‑secured puts, a liquidity squeeze on bad news could spike IV and create forced sellers — price options for that regime and size positions to survive >40% adverse moves.

Key Decisions for Investors

• Establish a cash‑secured short position: sell SRPT Jan‑2027 $15 puts size 1–2% of portfolio (max notional such that assignment equals ≤2% allocation), target premium ≈ $3.20; risk rules: close/roll at SRPT < $12 or unrealized loss >30%, plan to hold to Jan‑2027 if no assignment.
• If seeking downside protection instead of naked exposure, buy SRPT Jan‑2027 $10/$15 put spread sized 0.5–1% portfolio to cap downside to $5 per share (max loss) while keeping premium outlay limited; enter within 10% of current IV to avoid buying spikes.
• Initiate a 2–3% long position in NDAQ (stock or 12–18 month calls) to capture structurally higher options/clearing revenues if elevated biotech IV persists; trim this position if sector IV collapses >40% or volumes fall >20% vs. current run‑rate within 3 months.
• Reallocate 3–5% from idiosyncratic biotech single‑name exposure (including SRPT) into diversified healthcare (e.g., XLV) or biotech ETF (IBB) over the next 4–12 weeks to reduce binary event risk ahead of expected clinical/FDA catalysts.